Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
10/19/2020 10/20/2020 10/21/2020 10/22/2020 10/23/2020 Date
78.59(c) 77.77(c) 76.38(c) 76.63(c) 76.48(c) Last
4 739 760 6 027 953 5 958 018 6 697 531 5 021 855 Volume
-0.46% -1.04% -1.79% +0.33% -0.20% Change
More quotes
Financials (USD)
Sales 2020 49 708 M - -
Net income 2020 8 688 M - -
Net Debt 2020 18 119 M - -
P/E ratio 2020 20,7x
Yield 2020 3,73%
Sales 2021 52 942 M - -
Net income 2021 10 375 M - -
Net Debt 2021 13 133 M - -
P/E ratio 2021 17,2x
Yield 2021 3,87%
Capitalization 186 B 186 B -
EV / Sales 2020 4,11x
EV / Sales 2021 3,77x
Nbr of Employees 110 000
Free-Float 86,9%
More Financials
Company
Novartis is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by family of products as follows: - pharmaceutical products (79.5%): used to treat cardiovascular, respiratory, and dermatological diseases, gastrointestinal disorders, cancers, central nervous system disorders, hormone imbalances, etc.; - generic drugs (20.5%; Sandoz). Net sales... 
Sector
Pharmaceuticals
Calendar
10/22Presentation
More about the company
Notations Surperformance© of Novartis AG
Trading Rating : Investor Rating :
More Ratings
All news about NOVARTIS AG
10/23Why Merck Is Playing Catch-Up in the Coronavirus Vaccine Chase
DJ
10/23GLOBAL MARKETS LIVE : Intel, Mattel, Nordea…
10/23NOVARTIS : announces European Medicines Agency (EMA) has granted orphan drug des..
PU
10/22NOVARTIS : receives US Food and Drug Administration Orphan Drug Designation for ..
AQ
10/22NOVARTIS AG : quaterly earnings release
10/21NOVARTIS AG : Morgan Stanley keeps its Buy rating
MD
10/21NOVARTIS : receives US Food and Drug Administration (FDA) Orphan Drug Designatio..
PU
10/19AEQUUS PHARMACEUTICALS : Extends Commercial Agreement for Specialty Product Tacr..
AQ
10/16NOVARTIS : Genmab to Host Capital Markets Day
AQ
10/15Genmab Announces Data to be presented at SITC 35th Anniversary Annual Meeting
AQ
10/14NOVARTIS AG : UBS keeps its Buy rating
MD
10/13NOVARTIS AG : Goldman Sachs gives a Buy rating
MD
10/12NOVARTIS : received European Medicines Agency PRIME designation for iptacopan in..
AQ
10/09NOVARTIS AG : JP Morgan reiterates its Sell rating
MD
10/09NOVARTIS : received European Medicines Agency (EMA) PRIME designation for iptaco..
PU
More news
News in other languages on NOVARTIS AG
10/23Aktien Schweiz Schluss: SMI hält sich knapp über 10'000 Punkten
10/23Bourse Zurich: les indices terminent la semaine dans le vert
10/23DPA-AFX-ÜBERBLICK : UNTERNEHMEN vom 23.10.2020 - 15.15 Uhr
10/23Aktien Schweiz: SMI kämpft um 10'000er Marke
10/23Bourse Zurich: toujours sans direction à l'approche de la mi-journée
More news
Analyst Recommendations on NOVARTIS AG
More recommendations
Stock Trading Strategies
NOVARTIS - 2019
The underlying trend is in force again
BUY
More Stock Trading Analysis
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | MarketScreener
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 107,73 $
Last Close Price 84,53 $
Spread / Highest target 65,3%
Spread / Average Target 27,5%
Spread / Lowest Target -2,42%
EPS Revisions
Managers
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Elizabeth Theophille Chief Technology & Digital Officer
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG-16.78%185 999
JOHNSON & JOHNSON-0.43%381 970
ROCHE HOLDING AG-5.33%280 343
PFIZER INC.-2.55%207 994
MERCK & CO., INC.-12.23%200 341
NOVO NORDISK A/S14.86%164 146